High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia by Marco Herling, Kaushali.

Slides:



Advertisements
Similar presentations
Supplemental Figure S2. Location and H 2 O 2 -dependent binding of RBPs to biotinylated MKP-1 transcripts. (A) Schematic of the MKP-1 mRNA showing the.
Advertisements

Clinical Laboratory Analysis of Immunoglobulin Heavy Chain Variable Region Genes for Chronic Lymphocytic Leukemia Prognosis  Philippe Szankasi, David.
An anti-CD20–IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma by Stephen D. Gillies, Yan Lan, Steven Williams,
Cell Surface CD74–MIF Interactions Drive Melanoma Survival in Response to Interferon-γ  Keiji Tanese, Yuuri Hashimoto, Zuzana Berkova, Yuling Wang, Felipe.
Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival by Kai-Da Wu, Lisa.
2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells
by Pascal Gelebart, Mona Anand, Hanan Armanious, Anthea C
Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor–κB and IκBα kinase in human multiple myeloma cells, leading to.
The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCθ and ERK pathways by Gilles Despouy, Marjorie Joiner, Emilie Le Toriellec,
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas by Pankaj Gupta,
Synergistic action of dual IGF1/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation.
by Kumudha Balakrishnan, William G. Wierda, Michael J
Overexpression of survivin in primary ATL cells and sodium arsenite induces apoptosis by down-regulating survivin expression in ATL cell lines by Xiao-Fang.
Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia by Xue-Fei Huang, Shao-Kai Luo,
by Juan C. Rodríguez-Alba, Miguel E
RET Mutation and Expression in Small-Cell Lung Cancer
CD6 Ligation Modulates the Bcl-2/Bax Ratio and Protects Chronic Lymphocytic Leukemia B Cells From Apoptosis Induced by Anti-IgM by Lyda M. Osorio, Angelina.
by Christopher J. Ott, Nadja Kopp, Liat Bird, Ronald M
Volume 128, Issue 3, Pages (March 2005)
Focus on lymphomas Cancer Cell
by Rong Chen, Michael J. Keating, Varsha Gandhi, and William Plunkett
The tyrosine phosphatase SHP-1 dampens murine Th17 development
ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells by Tomohiko Tamura, Hee Jeong Kong, Chainarong Tunyaplin,
by Sanjai Sharma, and Alan Lichtenstein
Volume 136, Issue 5, Pages (May 2009)
Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells by Aleksandar Petlickovski,
Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor κB target genes and induction of apoptosis in chronic.
Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells by Sergey Krysov, Samantha Dias, Alex Paterson, C.
Interferon-γ Prevents Apoptosis in Epstein-Barr Virus-Infected Natural Killer Cell Leukemia in an Autocrine Fashion by Shin-ichi Mizuno, Koichi Akashi,
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial by Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka,
Reduction of CRKL expression in patients with partial DiGeorge syndrome is associated with impairment of T-cell functions  Mauro Giacomelli, PhD, Rajesh.
The PI3K/mTOR inhibitor PF induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model by Matthew D. Blunt,
FcRL6, a new ITIM-bearing receptor on cytolytic cells, is broadly expressed by lymphocytes following HIV-1 infection by Timothy J. Wilson, Rachel M. Presti,
by Beatriz Bellosillo, Mireia Dalmau, Dolors Colomer, and Joan Gil
by Andrea Crotti, Marina Lusic, Rossella Lupo, Patricia M. J
by Jun Yuan, David B. Lovejoy, and Des R. Richardson
Vascular endothelial growth factor stimulates protein kinase CβII expression in chronic lymphocytic leukemia cells by Simon T. Abrams, Benjamin R. B. Brown,
LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis by Albert Gutierrez,
KIR3DL2/CpG ODN Interaction Mediates Sézary Syndrome Malignant T Cell Apoptosis  Bouchra Ghazi, Nicolas Thonnart, Martine Bagot, Armand Bensussan, Anne.
An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti–IL-6 antibody-induced.
The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia by Christine Le Roy, Pierre-Antoine Deglesne, Nathalie.
LPS induces CD40 gene expression through the activation of NF-κB and STAT-1α in macrophages and microglia by Hongwei Qin, Cynthia A. Wilson, Sun Jung Lee,
Functional and Clinical Characterization of the Putative Tumor Suppressor WWOX in Non-small Cell Lung Cancer  Silvan Becker, MD, Boyka Markova, PhD, Rainer.
The BH3-mimetic GX synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak by Patricia Pérez-Galán, Gaël.
C-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma by Mauricio P. Oyarzo, L. Jeffrey Medeiros, Coralyn Atwell, Marianna.
Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells by Uri Rozovski, Ji Yuan Wu, David.
EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT by Akil A. Merchant, Aparna Jorapur, Amy McManus, Ren Liu, Valery Krasnoperov,
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,
Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia by Xavier Leleu, Lian Xu, Xiaoying Jia, Antonio Sacco, Mena Farag,
Clinical Laboratory Analysis of Immunoglobulin Heavy Chain Variable Region Genes for Chronic Lymphocytic Leukemia Prognosis  Philippe Szankasi, David.
Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma by Hanna Karvonen, David Chiron, Wilhelmiina Niininen,
Impaired Proteasome Function Activates GATA3 in T Cells and Upregulates CTLA-4: Relevance for Sézary Syndrome  Heather M. Gibson, Anjali Mishra, Derek.
by Kamira Maharaj, John J
Plexin B1 Suppresses c-Met in Melanoma: A Role for Plexin B1 as a Tumor-Suppressor Protein through Regulation of c-Met  Laurel Stevens, Lindy McClelland,
Inhibition of CRM1-Mediated Nucleocytoplasmic Transport: Triggering Human Melanoma Cell Apoptosis by Perturbing Multiple Cellular Pathways  Gaurav Pathria,
Myeloma cell–derived Runx2 promotes myeloma progression in bone
Keratinocyte growth factor promotes goblet cell differentiation through regulation of goblet cell silencer inhibitor  Dai Iwakiri, Daniel K. Podolsky 
ERK1/2 Is Highly Phosphorylated in Melanoma Metastases and Protects Melanoma Cells from Cisplatin-Mediated Apoptosis  Alireza Mirmohammadsadegh, Rodrigo.
Role of NF-κB Activity in Apoptotic Response of Keratinocytes Mediated by Interferon-γ, Tumor Necrosis Factor-α, and Tumor-Necrosis-Factor-Related Apoptosis-Inducing.
Volume 17, Issue 2, Pages (February 2009)
Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL by Kallesh D. Jayappa, Craig A.
Plexin C1, A Receptor for Semaphorin 7A, Inactivates Cofilin and Is a Potential Tumor Suppressor for Melanoma Progression  Glynis A. Scott, Lindy A. McClelland,
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
by Xuefang Cao, Xingming Deng, and W. Stratford May
The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.
Dual apoptotic signaling pathways triggered by IMMU-140: Anti–HLA-DR- and SN-38–mediated signals. Dual apoptotic signaling pathways triggered by IMMU-140:
Dysregulated NF-κB activation in Il1r8+/+/lpr and Il1r8−/−/lpr mice.
by Dana S. Levy, Jason A. Kahana, and Rakesh Kumar
WP1066 induces caspase-dependent apoptosis.
Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance by Taghi Manshouri, Kim-anh.
Presentation transcript:

High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia by Marco Herling, Kaushali A. Patel, Nicole Weit, Nils Lilienthal, Michael Hallek, Michael J. Keating, and Dan Jones Blood Volume 114(21):4675-4686 November 19, 2009 ©2009 by American Society of Hematology

Levels of TCL1 in CLL correlate with other features of aggressive disease. Levels of TCL1 in CLL correlate with other features of aggressive disease. (A) Increased expression of TCL1 (graded on immunoblots after normalization to β-actin levels) significantly correlated with tumor-cell ZAP70 immunohistochemical expression, unmutated IGHV gene mutational status, surface CD38 levels, and deletions of the chromosome 11q22-23 region. (B) TCL1 levels, using a 4-tier score described in “Methods,” showed a strong positive correlation with the percentage of sIgM+ CLL cells analyzed at the time of TCL1 measurement. Marco Herling et al. Blood 2009;114:4675-4686 ©2009 by American Society of Hematology

Higher TCL1 levels predict the degree of BCR-induced AKT phospho-activation in CLL short-term cultures. Higher TCL1 levels predict the degree of BCR-induced AKT phospho-activation in CLL short-term cultures. (A) After BCR crosslinking, responsive CLL cases showed rapid ERK1/2 phospho-activation followed by variable and usually prolonged pS473-AKT induction. pAKT activation could be detected in some cases by 15 minutes of BCR stimulation and was most variable between cases at 2 hours, peaked between 24 to 48 hours, and declined thereafter. Such responsive cases frequently showed parallel changes in TCL1 levels (see also Table 1). (B) Using 3 different α-IgM plate concentrations for each of the 70 CLL cultures, the degree of AKT phospho-activation after 2 hours of BCR engagement (graded as none, moderate, or strong) was highly correlated with TCL1 levels (P = .005, graded as in Figure 1). Among the strong pAKT responder group (red text), moderate to high TCL1 levels were seen in 24 of 25 cases, whereas 75% of the TCL1-dim/negative cases were in the nonresponsive group (black). A third group of cases showed moderate levels of pAKT induction, even at high α-IgM concentrations (blue, middle panel). (C) Full-length TCL1, introduced into the TCL1-negative DoHH2 B-cell line, showed both cytoplasmic and nuclear localization with most pAKT phospho-activation in the cytoplasmic fraction (left panel). TCL1 introduction led to mildly increased (1.26-fold) basal pAKT levels, compared with the TCL1− baseline (“*” in right panel) but more prominent phospho-activation after BCR (**1.72-fold after TCL1+ baseline was set as 1.0) or LPS stimulation, but not after other B-cell cytokine stimuli. Numbers indicate normalized densitometric quantitation of blot, with 1.0 corresponding to the level seen in the unstimulated control condition (blue indicates TCL1-expressing transfectants). Marco Herling et al. Blood 2009;114:4675-4686 ©2009 by American Society of Hematology

The growth response in CLL cultures after BCR engagement is most strongly predicted by pAKT activation and by TCL1 levels. The growth response in CLL cultures after BCR engagement is most strongly predicted by pAKT activation and by TCL1 levels. (A) The growth and apoptotic parameters of 29 CLL cultures from Figure 2B were measured after 48 hours of continuous BCR crosslinking at 3 different α-IgM concentrations, compared with CD40/IL-4 stimulation and unstimulated controls. Cases were defined as having a hyperresponsive BCR pattern (left panels, with growth at low α-IgM and apoptosis at higher doses), dose-dependent BCR response (center panels), or absent growth response (right panels) based on MTT assay (top panels) and immunoblots (middle panels). Increased cyclin D2 levels correlated with MTT-measured growth induction as did expression of the AKT target MCL1, whereas cleaved PARP and caspase 3 levels correlated with the degree of apoptosis observed. The 2-hour AKT phospho-activation pattern after BCR engagement (colored as in Figure 2B as follows: red, strong; blue, moderate; and black, absent) were correlated with the 48-hour growth pattern (bottom panel). Cases with a hyperresponsive growth pattern showed strong pAKT induction (red lines) that paralleled the BCR response pattern seen in tonsillar B cells (lines with square boxes), whereas cases with only moderate BCR induced pAKT activation showed dose-dependent growth patterns (blue lines). (B) The pattern of BCR-inducible growth at 48 hours correlated with TCL1 levels. A hyperresponsive/apoptotic outcome was seen in CLLs with the highest TCL1 expression, whereas a lower level but progressive increase of growth on α-IgM escalation (dose-dependent response) was associated with low to moderate TCL1 levels in most cases. CLL cultures not responding to BCR stimulation included those that were negative/low for TCL1 but also some that highly expressed TCL1 where the growth stimulation may have been missed because of timing of the MTT assay. Marco Herling et al. Blood 2009;114:4675-4686 ©2009 by American Society of Hematology

Marco Herling et al. Blood 2009;114:4675-4686 ©2009 by American Society of Hematology

Marco Herling et al. Blood 2009;114:4675-4686 ©2009 by American Society of Hematology

Higher TCL1 expression is associated with higher WBC and predicts poor clinical outcome, regardless of treatment. Higher TCL1 expression is associated with higher WBC and predicts poor clinical outcome, regardless of treatment. (A) Median and range of WBC at diagnosis in all 70 patients were significantly higher in CLLs with moderate or strong TCL1 expression compared with the TCL1-dim/negative cases. (B) Among untreated patients, CLL cases that strongly expressed TCL1 developed higher peak WBCs. (C) Higher TCL1 levels correlated with shorter PFS among all 59 treated patients and (D) with shorter OS in all 70 cases studied in culture. (E) PFS was shorter for patients with high-level TCL1 carrying tumors for both the 34 cases treated upfront with 1- or 2-drug fludarabine-containing regimens and (F) for the 22 cases treated with frontline 3- or 4-drug chemo-immunotherapy regimens. Marco Herling et al. Blood 2009;114:4675-4686 ©2009 by American Society of Hematology

Clinicopathologic features including TCL1 protein levels and their associations in the 70-case study set of BCR-stimulated CLL. Clinicopathologic features including TCL1 protein levels and their associations in the 70-case study set of BCR-stimulated CLL Marco Herling et al. Blood 2009;114:4675-4686 ©2009 by American Society of Hematology